Examples of such statements include statements about the potential timing of FDA clearance of our Magellan Robotic System in the U.S. the timing of first cases to be performed with the system, the potential benefit of the system on vascular procedures and the timing of commercializing our Magellan System.
Important factors that could cause actual results to differ materially from those indicated by such forward looking statements include among others engineering regulatory and sales challenges in developing new products and entering new markets, potential safety and regulatory issues that could slow or suspend our sales, the uncertain timelines caused and results of preclinical and clinical trials, the rate of adoption of our systems and the rate of use of our catheters, the scope and validity of intellectual property right applicable to our products, competition from other companies our ability to recruit and retain key personnel, our ability to maintain our remedial actions over previously reported material weaknesses internal control over financial reporting, the effect of credit, financial and economic conditions on capital spending by our potential customers, our ability to manage expenses and obtain additional financing and other risks more fully described in the risk factor section of our quarterly report on Form 10-Q for the quarter ended June 30, 2011 filed with the SEC on our August 8, 2011 and the risks discussed in other reports filed with the SEC.
Given these uncertainties you should not place undue reliance on the forward-looking statements included in our remarks and responses to questions. We undertake no obligation to revise or update information herein to reflect events or circumstance in the future even if new information become available.
And with that I will turn the call over to Hansen Medicals President and CEO Bruce Barclay.Bruce Barclay Thanks Pete good afternoon everyone and thank you for joining us today for our third quarter 2011 conference call. I will spend the next several minutes providing an update on the quarter and on recent developments with our new vascular robotic system called the Magellan Robotic System. Pete will then return to provide a review of our third quarter financial results.